| **Author, year** | **Study design1** | **Start year of enrollment / Length of followup** | **Location / Multicenter** | **Adherence reported / Adherence >80% in each study arm** | **Inclusion criteria** |
| --- | --- | --- | --- | --- | --- |
| Alemzadeh, 2002200 | Retrospective cohort | Start year: NR  Followup duration: NR | Europe  Single center | NA | Pediatrics, CD only, other criteria |
| Beaugerie, 2009130 | Prospective cohort | Start year: 2004  Median followup duration: 35 months | Europe  Multicenter | NA | Pediatrics, adults, IBD, other criteria |
| Candy, 199553 | RCT, parallel arms | Start year: NR  Duration of assigned treatment: 12 weeks | Africa  Single center | No | Pediatrics, adults, CD only, no previous surgery (extensive surgery for Crohn's disease), CDAI (>200), not pregnant, not nursing, other criteria |
| Cezard, 2009194 | RCT, parallel arms | Start year: 1991  Duration of assigned treatment: 1 years | Europe  Multicenter | No | Pediatrics, CD only, HBI (>5), no use of 5-aminosalicylate acids, thiopurines, methotrexate, active disease, other criteria |
| Crombe, 2011226  EPIMAD | Retrospective cohort | Start year: 1988  Median followup duration: 32 months | Europe  Multicenter | NA | Pediatrics, CD only, previous use of infliximab, other criteria |
| de Vries, 2008227 | Other study design | Start year: 1999  Median followup duration: 9 years | Europe  Single center | NA | Pediatrics, adults, IBD, no use of infliximab |
| D'Haens, 200848 | RCT, parallel arms | Start year: 2001  Duration of assigned treatment: 2 years | Europe  Multicenter | Yes  Yes | Pediatrics, adults, CD only, CDAI (>200), no use of corticosteroids, antimetabolites, biological agents, active disease, not pregnant, no obstructive symptoms with strictures, no history of TB, no cancer, other criteria |
| Escher, 2004190 | RCT, parallel arms | Start year: 1998  Duration of assigned treatment: 12 weeks | Europe  Multicenter | No | Pediatrics, CD only, CDAI (>200), no use of corticosteroids, thiopurines, active disease, other criteria |
| Griffiths, 1993221 | RCT, crossover | Start year: 1988  Duration of assigned treatment: 8 weeks | North America  Single center | No | Pediatrics, CD only, HBI (>4), other criteria |
| Issenman, 1993196 | Prospective cohort | Start year: NR Mean followup duration: 2 years | North America  Single center | NA | Pediatrics, CD only, males, active disease |
| Lees, 2009145 | Retrospective cohort | Start year: 1999  Median followup duration: 2.4 years | Europe  Multicenter | NA | Pediatrics, adults, IBD, not pregnant, other criteria |
| Levine, 2002198 | Case-control study | Start year: NR  Followup duration: NR | Israel  Multicenter | NA | Pediatrics, CD only, PCDAI (12.5-40), no use of thiopurines, mild-moderate disease, other criteria |
| Levine, 2003191 | RCT, parallel arms | Start year: NR  Duration of assigned treatment: 12 weeks | Israel  Multicenter | No | Pediatrics, CD only, no previous surgery (in past 6 weeks), PCDAI (12.5-40), no use of corticosteroids, thiopurines, active disease, other criteria |
| Malik, 2011229  Royal Hospital Sick Children | Retrospective cohort | Start year: 2003  Mean followup duration: 12 months | Europe  Single center | NA | Pediatrics, CD only, other criteria |
| Markowitz, 2000192 | RCT, parallel arms | Start year: NR  Duration of assigned treatment: 18 months | US  Multicenter | No | Pediatrics, CD only, moderate-severe disease, other criteria |
| Mate-Jimenez, 200052 | RCT, parallel arms | Start year: 1994  Duration of assigned treatment: 26.5 months | Europe  Single center | No | Pediatrics, adults, IBD, no previous surgery (extensive surgery), previous use of corticosteroids, not pregnant, not nursing, using adequate contraception, no abscess, other criteria |
| Present, 198060 | RCT, parallel arms, crossover | Start year: NR  Duration of assigned treatment: 1 years | US  Single center | Yes  No | Pediatrics, adults, CD only, active disease, other criteria |
| Rhodes, 197161 | RCT, crossover | Start year: NR  Duration of assigned treatment: 2 months | Location: NR  Number of centers NR | Yes  No | Pediatrics, adults, CD only |
| Russell, 2011236 | Prospective cohort | Start year: 2008  Median followup duration: 0.8 years | Europe  Multicenter | NA | Pediatrics, IBD, other criteria |
| Saha, 1998197 | Prospective cohort | Start year: 1982  Followup duration: NR | Europe  Single center | NA | Pediatrics, IBD |
| Thayu, 2010199 | Case-control study | Start year: NR  Mean followup duration: 43 months | US  Single center | NA | Pediatrics, CD only, no use of any medications affecting growth and development, other criteria |
| Thayu, 2010237  CHOP | Prospective cohort | Start year: NR | US  Single center | NA | Pediatrics, CD only, other criteria |
| Thomson, 1990224 | RCT, parallel arms | Start year: NR  Duration of assigned treatment: 12 months | North America, Europe, Africa  Multicenter | Yes  Yes | Pediatrics, CD only, CDAI (<150), no use of azathioprine, metronidazole, no ostomy, no obstructive symptoms with strictures, other criteria |
| Van Assche, 200889 | RCT, parallel arms | Start year: 2004  Duration of assigned treatment: 2 years | Europe  Multicenter | No | Pediatrics, adults, CD only, previous use of methotrexate, infliximab, immunosuppressives (azathioprine/6-MP or methotrexate), perianal fistulizing, not pregnant, not nursing, other criteria |

Abbreviations: 6-MP = 6-mercaptopurine; CD = Crohn’s disease; CDAI = Crohn’s Disease Activity Index; HBI = Harvey-Bradshaw Index; IBD = irritable bowel disease; PCDAI = Pediatric Crohn’s Disease Activity Index; NR = not reported; RCT = randomized controlled trial; TB = tuberculosis; US = United States